GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novartis AG (BSP:N1VS34) » Definitions » Cyclically Adjusted PB Ratio

Novartis AG (BSP:N1VS34) Cyclically Adjusted PB Ratio : 3.44 (As of May. 26, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Novartis AG Cyclically Adjusted PB Ratio?

As of today (2024-05-26), Novartis AG's current share price is R$52.25. Novartis AG's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was R$15.21. Novartis AG's Cyclically Adjusted PB Ratio for today is 3.44.

The historical rank and industry rank for Novartis AG's Cyclically Adjusted PB Ratio or its related term are showing as below:

BSP:N1VS34' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 2.23   Med: 2.77   Max: 3.5
Current: 3.29

During the past years, Novartis AG's highest Cyclically Adjusted PB Ratio was 3.50. The lowest was 2.23. And the median was 2.77.

BSP:N1VS34's Cyclically Adjusted PB Ratio is ranked worse than
70.66% of 692 companies
in the Drug Manufacturers industry
Industry Median: 1.89 vs BSP:N1VS34: 3.29

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Novartis AG's adjusted book value per share data for the three months ended in Mar. 2024 was R$96.830. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is R$15.21 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Novartis AG Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Novartis AG's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novartis AG Cyclically Adjusted PB Ratio Chart

Novartis AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.14 2.94 2.79 2.81 3.04

Novartis AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.79 3.00 3.16 3.04 3.13

Competitive Comparison of Novartis AG's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - General subindustry, Novartis AG's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novartis AG's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novartis AG's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Novartis AG's Cyclically Adjusted PB Ratio falls into.



Novartis AG Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Novartis AG's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=52.25/15.21
=3.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novartis AG's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Novartis AG's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=96.83/107.3549*107.3549
=96.830

Current CPI (Mar. 2024) = 107.3549.

Novartis AG Quarterly Data

Book Value per Share CPI Adj_Book
201406 64.874 101.517 68.605
201409 68.946 101.247 73.105
201412 77.943 100.704 83.091
201503 99.131 100.339 106.063
201506 101.478 100.464 108.439
201509 124.973 99.785 134.453
201512 125.954 99.386 136.053
201603 111.522 99.475 120.356
201606 104.168 100.088 111.731
201609 102.689 99.604 110.680
201612 105.720 99.380 114.204
201703 89.354 100.040 95.888
201706 98.344 100.285 105.277
201709 97.742 100.254 104.665
201712 105.453 100.213 112.968
201803 100.022 100.836 106.489
201806 124.761 101.435 132.042
201809 138.625 101.246 146.990
201812 132.093 100.906 140.535
201903 78.091 101.571 82.538
201906 86.520 102.044 91.023
201909 95.546 101.396 101.161
201912 100.526 101.063 106.784
202003 108.675 101.048 115.459
202006 121.975 100.743 129.980
202009 129.353 100.585 138.060
202012 129.022 100.241 138.179
202103 126.811 100.800 135.058
202106 121.494 101.352 128.690
202109 133.966 101.533 141.648
202112 171.182 101.776 180.566
202203 138.411 103.205 143.977
202206 145.514 104.783 149.086
202209 148.264 104.835 151.828
202212 146.854 104.666 150.626
202303 129.306 106.245 130.657
202306 121.672 106.576 122.562
202309 91.698 106.570 92.374
202312 111.867 106.461 112.806
202403 96.830 107.355 96.830

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Novartis AG  (BSP:N1VS34) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Novartis AG Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Novartis AG's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Novartis AG (BSP:N1VS34) Business Description

Address
Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Novartis AG (BSP:N1VS34) Headlines

No Headlines